基于"肺主治节"理论对玉屏风散合四君子汤干预反复呼吸道感染大鼠肺心共损研究OA

This study aims to validate the intervention effect of Yupingfeng Powder and Sijunzi Decoction(YPSD)on"lung's failure in management and regulation"in rats with recurrent respiratory tract infection(RRTI)by utilizing macroscopic characterization evaluation and comparing lung and heart tissue damage.Additionally,it aims to predict the possible mechanisms underlying co-treatment of RRTI and myocardial damage(MD)based on network pharmacology methods.Thirty rats were randomly divided into a control(Co)group,a model(Mo)group,a pidotimod(Pg)group,a low-dose YPSD(Lg)group,and a high-dose YPSD(Hg)group.After the RRTI modeling and interventions,macroscopic characterization indicators were evaluated based on the manifestations of"lung's failure in management and regulation".The levels of lung and heart tissue damage were compared.Network pharmacology experiments were used to predict potential therapeutic targets and possible mechanisms of YPSD in treating RRTI and MD,which were further validated through in vivo experiments.The experimental results showed that YPSD could effectively improve the macroscopic characterization evaluation indicators in RRTI rats and alleviate the damage levels of lung and heart tissue during the pathological process.Network pharmacology results identified protein kinase B(Akt)as the core functional protein.In vivo experimental results demonstrated that YPSD could effectively upregulate the activated Akt protein levels in lung and heart tissue,with a significantly increased ratio of B lymphoblastoma-2 gene(Bcl-2)to Bcl-2-associated X protein(Bax).YPSD can effectively intervene in the outcome of"lung's failure in management and regulation"in RRTI rats,achieving the effect of concurrent lung and heart treatment.Its intervention effects on RRTI and MD may function by regulating the activation level of the Akt protein.